Tumor progression in the LPB-Tag transgenic model of prostate cancer is altered by vitamin D receptor and serum testosterone status
- PMID: 20347977
- PMCID: PMC4211603
- DOI: 10.1016/j.jsbmb.2010.03.062
Tumor progression in the LPB-Tag transgenic model of prostate cancer is altered by vitamin D receptor and serum testosterone status
Abstract
Previous studies have suggested that 1,25 dihydroxyvitamin D(3) (1,25(OH)2D3) induces cell cycle arrest and/or apoptosis in prostate cancer cells in vitro, suggesting that vitamin D may be a useful adjuvant therapy for prostate cancer and a chemopreventive agent. Most epidemiological data however shows a weak link between serum 25(OH)D3 and risk of prostate cancer. To explore this dichotomy we have compared tumor progression in the LPB-Tag model of prostate in VDR knock out (VDRKO) and wild type (VDRWT) mice. On the C57BL/6 background LPB-Tag tumors progress significantly more rapidly in the VDRKO mice. VDRKO tumors show significantly higher levels of cell proliferation than VDRWT tumors. In mice supplemented with testosterone to restore the serum levels to the normal range, these differences in tumor progression, and proliferation are abrogated, suggesting that there is considerable cross-talk between the androgen receptor (AR) and the vitamin D axis which is reflected in significant changes in steady state mRNA levels of the AR, PCNA, cdk2 survivin and IGFR1 and 2 genes. These alterations may explain the differences between the in vitro data and the epidemiological studies.
Copyright (c) 2010 Elsevier Ltd. All rights reserved.
Figures




Similar articles
-
Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.Prostate. 2005 Sep 1;64(4):362-72. doi: 10.1002/pros.20251. Prostate. 2005. PMID: 15754350
-
Characterization of mammary tumor cell lines from wild type and vitamin D3 receptor knockout mice.Mol Cell Endocrinol. 2003 Feb 28;200(1-2):67-80. doi: 10.1016/s0303-7207(02)00416-1. Mol Cell Endocrinol. 2003. PMID: 12644300
-
Vitamin D and testosterone co-ordinately modulate intracellular zinc levels and energy metabolism in prostate cancer cells.J Steroid Biochem Mol Biol. 2019 May;189:248-258. doi: 10.1016/j.jsbmb.2019.01.006. Epub 2019 Jan 18. J Steroid Biochem Mol Biol. 2019. PMID: 30664926
-
Vitamin D and systemic cancer: is this relevant to malignant melanoma?Br J Dermatol. 2002 Aug;147(2):197-213. doi: 10.1046/j.1365-2133.2002.04960.x. Br J Dermatol. 2002. PMID: 12174089 Review.
-
Vitamin D in Prostate Cancer.Vitam Horm. 2016;100:321-55. doi: 10.1016/bs.vh.2015.10.012. Epub 2015 Dec 8. Vitam Horm. 2016. PMID: 26827958 Review.
Cited by
-
Effects of 1α,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells.Mol Cancer. 2011 May 18;10:58. doi: 10.1186/1476-4598-10-58. Mol Cancer. 2011. PMID: 21592394 Free PMC article.
-
Cellular and molecular effects of vitamin D on carcinogenesis.Arch Biochem Biophys. 2012 Jul 1;523(1):107-14. doi: 10.1016/j.abb.2011.10.019. Epub 2011 Nov 9. Arch Biochem Biophys. 2012. PMID: 22085499 Free PMC article. Review.
-
Vitamin D Signaling Suppresses Early Prostate Carcinogenesis in TgAPT121 Mice.Cancer Prev Res (Phila). 2019 Jun;12(6):343-356. doi: 10.1158/1940-6207.CAPR-18-0401. Epub 2019 Apr 26. Cancer Prev Res (Phila). 2019. PMID: 31028080 Free PMC article.
-
Molecular link between vitamin D and cancer prevention.Nutrients. 2013 Sep 30;5(10):3993-4021. doi: 10.3390/nu5103993. Nutrients. 2013. PMID: 24084056 Free PMC article. Review.
-
1,25-Dihydroxyvitamin D(3) regulates PTHrP expression via transcriptional, post-transcriptional and post-translational pathways.Mol Cell Endocrinol. 2011 Aug 6;342(1-2):32-40. doi: 10.1016/j.mce.2011.05.025. Epub 2011 Jun 1. Mol Cell Endocrinol. 2011. PMID: 21664243 Free PMC article.
References
-
- Zhuang SH, Burnstein KL. Antiproliferative effects of 1α,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin dependent kinase-2 activity and persistent G1 accumulation. Endocrinol. 1998;139:1197–1207. - PubMed
-
- Peehl DM, Sellers RG. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res. 1994;54:805–810. - PubMed
-
- Murthy S, Agoulnik IU, Weigel NL. Androgen receptor signaling and Vitamin D receptor action in prostate cancer cells. Prostate. 2005;64:362–372. - PubMed
-
- Freedman LP. Transcriptional Targets of the Vitamin D3 Receptor-Mediating Cell Cycle Arrest and Differentiation. J Nutr. 1999;129:581S–586S. - PubMed
-
- Yang ES, Burnstein KL. Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and cdk2 mislocalization to the cytoplasm. J Biol Chem. 2003;278:46864–46868. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous